Among patients with de novo metastatic HNSCC, there do not appear to be major differences in patterns of metastasis between HPV+ and HPV- disease. Nearly half (40%) had oligometastatic disease, and survival was better when immunotherapy and higher dose radiation (50 Gy or more) were used. | Ruhle, Radiother Oncol 2026
